lactose has been researched along with Parkinson Disease in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (37.50) | 18.7374 |
| 1990's | 5 (62.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Block, GA; Cutler, NR; Sramek, JJ | 1 |
| Cutler, NR; Hand, EL; McLean, LF; Porras, AG; Reines, SA; Sramek, JJ | 1 |
| Diederich, NJ; Goetz, CG | 1 |
| Ahlskog, JE; Bailey, PA; Muenter, MD; Stevens, PM | 1 |
| Ahlskog, JE; Ahrens, S; Block, GA; Cedarbaum, JM; Cyhan, G; Goetz, CG; Koller, WC; LeWitt, PA; Liss, C; McLean, L | 1 |
| Baumann, G; Chin, L; Lieberman, A | 1 |
| Carter, SM; Hunter, KR; Sandler, M; Stern, GM; Youdim, MB | 1 |
| Barbeau, A; Botez, MI; Joubert, M; Mars, H | 1 |
1 review(s) available for lactose and Parkinson Disease
| Article | Year |
|---|---|
Dopaminergic agonists in the treatment of Parkinson's disease.
Topics: Apomorphine; Bromocriptine; Dopamine Agents; Humans; Lactose; Lisuride; Methylcellulose; Oxazines; Parkinson Disease; Pergolide; Receptors, Dopamine | 1992 |
2 trial(s) available for lactose and Parkinson Disease
| Article | Year |
|---|---|
Effect of MK-458 (HPMC) in Parkinson's disease previously untreated with dopaminergic drugs. A double-blind, placebo-controlled multicenter study.
Topics: Aged; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Lactose; Male; Methylcellulose; Middle Aged; Oxazines; Parkinson Disease | 1991 |
Amantadine-HCl (Symmetrel) in the management of Parkinson's disease: a double-blind cross-over study.
Topics: Age Factors; Alkaline Phosphatase; Amantadine; Blood Glucose; Blood Urea Nitrogen; Clinical Trials as Topic; Dihydroxyphenylalanine; Dopamine; Female; Humans; L-Lactate Dehydrogenase; Lactose; Male; Parasympatholytics; Parkinson Disease; Placebos; Sex Factors; Time Factors; Uric Acid; White People | 1971 |
5 other study(ies) available for lactose and Parkinson Disease
| Article | Year |
|---|---|
Poor tolerability of MK-458.
Topics: Humans; Lactose; Methylcellulose; Oxazines; Parkinson Disease | 1993 |
Pharmacokinetics and dose proportionality of D2-agonist MK-458 (HPMC) in parkinsonism.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Delayed-Action Preparations; Dopamine Agents; Dose-Response Relationship, Drug; Female; Humans; Lactose; Male; Methylcellulose; Middle Aged; Oxazines; Parkinson Disease; Tablets | 1992 |
Dopamine agonist treatment of fluctuating parkinsonism. D-2 (controlled-release MK-458) vs combined D-1 and D-2 (pergolide)
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Lactose; Levodopa; Male; Methylcellulose; Middle Aged; Oxazines; Parkinson Disease; Pergolide | 1992 |
MK 458, a selective and potent D2 receptor agonist in advanced Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Dopamine Agents; Female; Humans; Hypromellose Derivatives; Lactose; Levodopa; Lisuride; Methylcellulose; Middle Aged; Nausea; Oxazines; Parkinson Disease; Pergolide; Psychomotor Performance; Receptors, Dopamine | 1988 |
Enhanced tyramine conjugation in Parkinson's disease.
Topics: Glucuronates; Glucuronidase; Humans; Lactose; Parkinson Disease; Sulfatases; Sulfuric Acids; Time Factors; Tryptamines | 1974 |